Levels of SARS-CoV-2 Lineage P.1 Neutralization by Antibodies Elicited after Natural Infection and Vaccination

Souza, William Marciel de; Amorim, Mariene R.; Sesti-Costa, Renata; Coimbra, Laís D.; Toledo-Teixeira, Daniel Augusto de; Parise, Pierina Lorencini; Barbosa, Priscilla P; Bispo-dos-Santos, Karina; Mofatto, Luciana Souto; Simeoni, Camila L.; Brunetti, Natália S; Claro, Ingra Morales; Duarte, Adriana Silva Santos; Coletti, Thaís M.; Zangirolami, Audrey Basso; Costa-Lima, Carolina; Gomes, Arilson Bernardo SP; Buscaratti, Lucas I; Sales, Flavia Cristina da Silva; Costa, Vitor Antonio da; Franco, Lucas Augusto Moysés; Candido, Darlan S.; Pybus, Oliver G.; Jesus, Jaqueline Góes de; Silva, Camila A. M.; Ramundo, Mariana Severo; Ferreira, Giulia Magalhães; Pinho, Mariana C.; Souza, Luciano Melo de; Rocha, Elyrose Sousa Brito; Andrade, Pâmela S; Crispim, Myuki Alfaia Esashika; Maktura, Grazielle Celeste; Manuli, Erika R.; Santos, Magnun Nueldo Nunes; Camilo, Cecília Cunha; Angerami, Rodrigo Nogueira; Moretti, Maria Luíza; Spilki, Fernando Rosado; Arns, Clarice Weis; Addas‐Carvalho, Marcelo; Benites, Bruno Deltreggia; Mori, Marcelo Alves Silva; Gaburo, Nelson; Dye, Christopher; Wu, Chieh‐Hsi; Marques-Souza, Henrique; Marques, Rafael Elias; Farias, Alessandro Santos; Diamond, Michael S.; Faria, Nuno R.; Sabino, Éster Cerdeira; Granja, Fabiana; Proença-Módena, José Luiz

doi:10.2139/ssrn.3793486

Cited by 35 publications

(34 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Additionally, in a recent report, the immune plasma of COVID-19 convalescent blood donors had 6-fold less neutralizing capacity against the P.1 than against the B-lineage. Moreover, five months after booster immunization with CoronaVac, the plasma from vaccinated individuals failed to efficiently neutralize P.1 lineage isolates [20]. This reinforces the hypothesis of potential emerging reinfections, particularly in South America.…”

Section: Discussionsupporting

confidence: 65%

“…Positive selection stands as one of the most likely scenarios promoting virus adaptation and lineage-specific selection by attempting to relieve the pressure imposed by the host [20], thus setting the stage for possible cases of reinfection. On the other hand, prolonged infection in an immunocompromised host may contribute to relieving the virus from the pressure exerted by the immune system, leading to insidious intra-host mutation events and adaptation, which may also contribute to the emergence of new virus variants.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Phylogenomic Evidence of Reinfection and Persistence of SARS-CoV-2: First Report from Colombia

et al. 2021

View full text Add to dashboard Cite

The continuing evolution of SARS-CoV-2 and the emergence of novel variants have raised concerns about possible reinfection events and potential changes in the coronavirus disease 2019 (COVID-19) transmission dynamics. Utilizing Oxford Nanopore technologies, we sequenced paired samples of three patients with positive RT-PCR results in a 1–2-month window period, and subsequent phylogenetics and genetic polymorphism analysis of these genomes was performed. Herein, we report, for the first time, genomic evidence of one case of reinfection in Colombia, exhibiting different SARS-CoV-2 lineage classifications between samples (B.1 and B.1.1.269). Furthermore, we report two cases of possible viral persistence, highlighting the importance of deepening our understanding on the evolutionary intra-host traits of this virus throughout different timeframes of disease progression. These results emphasize the relevance of genomic surveillance as a tool for understanding SARS-CoV-2 infection dynamics, and how this may translate effectively to future control and mitigations efforts, such as the national vaccination program.

show abstract

Section: Discussionsupporting

confidence: 65%

Section: Discussionmentioning

confidence: 99%

Phylogenomic Evidence of Reinfection and Persistence of SARS-CoV-2: First Report from Colombia

et al. 2021

View full text Add to dashboard Cite

show abstract

“…These observations of decreased vaccine efficacy against B.1.351 correspond with significantly decreased neutralizing antibody titers against the B.1.351 variant compared to the original strain in vaccinee sera ( 5, 8, 9,10 ). Subjects vaccinated with CoronaVac, an inactivated SARS-CoV-2 vaccine, demonstrated no detectable neutralizing antibody titers against the P.1 variant ( 11 ).…”

Section: Introductionmentioning

confidence: 99%

Broad neutralization against SARS-CoV-2 variants induced by a modified B.1.351 protein-based COVID-19 vaccine candidate

et al. 2021

Preprint

View full text Add to dashboard Cite

Beginning in late 2020, the emergence and spread of multiple variant SARS-CoV-2 strains harboring mutations which may enable immune escape necessitates the rapid evaluation of second generation COVID-19 vaccines, with the goal of inducing optimized immune responses that are broadly protective. Here we demonstrate in a mouse immunogenicity study that two doses of a modified B.1.351 spike (S)-Trimer vaccine (B.1.351 S-Trimer) candidate can induce strong humoral immune responses that can broadly neutralize both the original SARS-CoV-2 strain (Wuhan-Hu-1) and Variants of Concern (VOCs), including the UK variant (B.1.1.7), South African variant (B.1.351) and Brazil variant (P.1). Furthermore, while immunization with two doses (prime-boost) of Prototype S-Trimer vaccine (based on the original SARS-CoV-2 strain) induced lower levels of cross-reactive neutralization against the B.1.351 variant, a third dose (booster) administered with either Prototype S-Trimer or B.1.351 S-Trimer was able to increase neutralizing antibody titers against B.1.351 to levels comparable to neutralizing antibody titers against the original strain elicited by two doses of Prototype S-Trimer.

show abstract

“…The spread of new SARS-CoV-2 variants represents a serious threat worldwide and, recently, it has been shown that an artificially created virus (pseudovirus) carrying the same mutations as the Brazilian P.1 variant also escaped from anti-receptor-binding domain (RBD) monoclonal antibodies and sera or plasma from convalescent or Pfizer BNT162b2vaccinated individuals [6]. Another study showed that the immune plasma of COVID-19 convalescent blood donors had six-fold less neutralizing capacity against the P.1 lineage with respect to the B lineage [7]. Here, we described a fully BNT162b2-vaccinated 83-yearold man infected with the Brazilian P.1 SARS-CoV-2 variant.…”

Section: Discussionmentioning

confidence: 99%

Mild Symptomatic SARS-CoV-2 P.1 (B.1.1.28) Infection in a Fully Vaccinated 83-Year-Old Man

Fabiani¹,

Margiotti²,

Viola³

et al. 2021

Pathogens

View full text Add to dashboard Cite

The novel severe acute respiratory syndrome coronavirus (SARS-CoV-2) and the associated coronavirus disease 2019 (COVID-19) continue to spread throughout the world, causing more than 120 million infections. Several variants of concern (VOCs) have emerged and spread with implications for vaccine efficacy, therapeutic antibody treatments, and possible reinfections. On 17 March 2021, several VOCs were detected, including lineage B.1.1.7, first identified in the UK, B.1.351 in South Africa, Lineage P.1 (B.1.1.28.1) in Brazil, and novel Sub-Lineage A (A.23.1), reported in Uganda, and B.1.525, reported in Nigeria. Here, we describe an 83-year-old man infected with the SARS-CoV-2 P.1 variant after two doses of the BNT162b2 mRNA COVID-19 vaccine.

show abstract

Levels of SARS-CoV-2 Lineage P.1 Neutralization by Antibodies Elicited after Natural Infection and Vaccination

Cited by 35 publications

References 0 publications

Phylogenomic Evidence of Reinfection and Persistence of SARS-CoV-2: First Report from Colombia

Phylogenomic Evidence of Reinfection and Persistence of SARS-CoV-2: First Report from Colombia

Broad neutralization against SARS-CoV-2 variants induced by a modified B.1.351 protein-based COVID-19 vaccine candidate

Mild Symptomatic SARS-CoV-2 P.1 (B.1.1.28) Infection in a Fully Vaccinated 83-Year-Old Man

Contact Info

Product

Resources

About